Promising combo for tough breast cancer passes early safety test
NCT ID NCT03109080
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This early-phase study tested the drug olaparib together with radiation therapy in 24 women with a hard-to-treat type of breast cancer called triple-negative breast cancer (TNBC). The main goal was to find the safest dose of olaparib when given with radiation and to check for side effects. The study included patients whose cancer had spread or come back after initial treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY SIDE EFFECT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.